Literature DB >> 2026482

Relationship between glutathione levels and drug or radiation sensitivities in human gastric cancer cell lines in vitro.

S C Barranco1, B Weintraub, K K MacLean, E G Beasley, V K Jenkins, C M Townsend.   

Abstract

Permanent cell lines and clones established from an untreated patient (AGS cells) with gastric carcinoma, and from a similar patient who had been treated with Adriamycin, 5FU and cytoxan (SII cells) were used in a study that compared their drug and radiation survival sensitivities to their glutathidine (GSH) values. The SII parental cell line was more resistant than the AGS cells in vitro to chlorambucil, ACT D, Adria, Bleo, and X-rays. This greater resistance was positively correlated with GSH values that were 1.77 times higher than in the AGS parental cell line. By contrast the SII parental cells were more sensitive than the AGS cells to MeCCNU and Melphalan. The drug and radiation sensitivities expressed among the clones of the two cell lines were heterogeneous and did not correlate with their GSH values.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2026482     DOI: 10.1007/bf00194541

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  30 in total

1.  Radiation sensitivity and study of glutathione and related enzymes in human colorectal cancer cell lines.

Authors:  J Carmichael; J G Park; W G Degraff; J Gamson; A F Gazdar; J B Mitchell
Journal:  Eur J Cancer Clin Oncol       Date:  1988-07

2.  Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells.

Authors:  H E Skipper; F M Schabel; H H Lloyd
Journal:  Semin Hematol       Date:  1978-07       Impact factor: 3.851

3.  Interactions between tumor subpopulations affecting their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate.

Authors:  B E Miller; F R Miller; G H Heppner
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

4.  Glutathione as a determinant of cellular response to doxorubicin.

Authors:  F Y Lee; A R Vessey; D W Siemann
Journal:  NCI Monogr       Date:  1988

5.  A fluorometric assay for glutathione.

Authors:  V H Cohn; J Lyle
Journal:  Anal Biochem       Date:  1966-03       Impact factor: 3.365

6.  Glutathione content of cultured cells and rodent brain regions: a specific fluorometric assay.

Authors:  L C Mokrasch; E J Teschke
Journal:  Anal Biochem       Date:  1984-08-01       Impact factor: 3.365

7.  Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells.

Authors:  R A Hromas; P A Andrews; M P Murphy; C P Burns
Journal:  Cancer Lett       Date:  1987-01       Impact factor: 8.679

8.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines.

Authors:  N Kartner; J R Riordan; V Ling
Journal:  Science       Date:  1983-09-23       Impact factor: 47.728

9.  Modification of SR 2508 sensitization in hypoxic V79 cells by manipulation of glutathione levels.

Authors:  T L Phillips; J B Mitchell; W G DeGraff; A Russo; N Albright; R Rajpal
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-05       Impact factor: 7.038

10.  The effect of glutathione (GSH) depletion in vivo by buthionine sulfoximine (BSO) on the radiosensitization of SR 2508.

Authors:  R A Kramer; M Soble; A E Howes; V P Montoya
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-05       Impact factor: 7.038

View more
  2 in total

1.  Morphology and infectivity of virus that persistently caused infection in an AGS cell line.

Authors:  Yukimasa Ooi; Eriko Daikoku; Hong Wu; Hiroaki Aoki; Chizuko Morita; Takashi Nakano; Takehiro Kohno; Tomohiko Takasaki; Kouichi Sano
Journal:  Med Mol Morphol       Date:  2011-12-17       Impact factor: 2.309

2.  Selenite-induced inhibition of colony formation by buthionine sulfoximine-sensitive and resistant cell lines.

Authors:  P B Caffrey; G D Frenkel
Journal:  Biol Trace Elem Res       Date:  1992-11       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.